Par Pharmaceutical, Inc.
One Ram Ridge Road
149 articles with Par Pharmaceutical, Inc.
Endo International plc today announced that its subsidiaries Endo Pharmaceuticals Inc. and Par Pharmaceutical, Inc. have executed a Settlement Agreement with the State of Oklahoma.
Endo International plc announced that one of its operating companies, Par Pharmaceutical, has received approval for and launched generic Afinitor® 2.5 mg, 5 mg and 7 mg tablets.
Par Pharmaceutical, Inc. Issues Voluntary Nationwide Recall of One Lot of Mycophenolate Mofetil for Injection, USP Due to the Presence of a Glass Fragment Observed in One Vial of Reconstituted Product
One vial of product was observed containing a glass fragment after reconstitution.
Endo International plc announced that Par Pharmaceutical, Inc., its wholly-owned subsidiary, priced $1.5 billion aggregate principal amount of 7.500% senior secured notes due 2027 at an issue price of $1,000 per $1,000 principal amount in connection with its previously announced private offering, which represents an upsize of $500.0 million over the previously contemplated offering amount.
Endo Announces Termination of Acquisition Agreements with Somerset Therapeutics and Business of Affiliate Wintac Limited
Endo International plc announced that its subsidiaries, Endo Ventures Limited, Par Pharmaceutical, Inc.
Recently, in the U.S., there has been a shortage of an anti-anxiety drug, buspirone. The American Society of Health-System Pharmacists (ASHP) lists shortages, and as of Jan. 31, 2019, noted shortages of buspirone tablets manufactured by Accord Healthcare, Mylan and Teva Pharmaceutical.
Endo Begins Shipment of Authorized Generic Version of INVANZ® (ertapenem for injection) in the United States
Endo International plc announced today that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version of Merck's INVANZ® (ertapenem for injection)
Endo Begins Shipment of Authorized Generic Version of Colcrys® (colchicine, USP) in the United States
Endo International plc announced that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping an authorized generic version of Takeda Pharmaceutical's Colcrys® (colchicine, USP) 0.6 mg tablets.
Indivior PLC today announced that its U.S. subsidiary, Indivior Inc., together with Aquestive Therapeutics Inc., entered into a settlement agreement with Par Pharmaceutical, Inc., Par Pharmaceutical Companies Inc., Endo International PLC and IntelGenx Technologies Corp., resolving patent litigation related to SUBOXONE® Sublingual Film.
Endo Obtains Preliminary Injunction Against QuVa Pharma, Inc. Preventing Marketing and Release of Vasopressin Product
Endo International plc announced that its subsidiaries, Par Pharmaceutical, Inc. and Par Sterile Products, LLC (Par), have obtained a preliminary injunction preventing QuVa Pharma, Inc. (QuVa) from marketing and releasing its planned vasopressin product that would compete with Par's Vasostrict®, the first and only vasopressin injection, USP, product approved by the U.S. Food and Drug Administration.
Endo International Announces Termination Of HSR Act Waiting Period In Connection With Its Proposed Acquisition Of Par Pharma